We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

RNA Sequencing as Alternative to Immunohistochemistry in Cancer Diagnostics

By LabMedica International staff writers
Posted on 06 Jul 2020
Print article
Image: The Bioanalyzer RNA 6000 Nano assay provides reliable and reproducible characterization of total RNA and mRNA from multiple sample types (Photo courtesy of Agilent Technologies).
Image: The Bioanalyzer RNA 6000 Nano assay provides reliable and reproducible characterization of total RNA and mRNA from multiple sample types (Photo courtesy of Agilent Technologies).
The conventionally used method for cancer diagnostics relies on immunohistochemical dyeing of tumor tissue sections. It allows detecting the presence and measuring the concentration of marker proteins characterizing malignant growths. The resulting microscope images indicate whether the tumor is malignant and what its molecular type is. This information is crucial for selecting the right therapy.

Another alternative method is RNA sequencing which involves determining the sequence and the number of molecules for each RNA present in the cell. The resulting data, referred to as the transcriptome, reflects the activity of all genes in the cell. To analyze such vast arrays of data, bioinformaticians employ specialized algorithms and compile transcriptome databases for different human cells and tissues.

Scientists at the Moscow Institute of Physics and Technology (MIPT, Moscow, Russia) and their associates examined biosamples of tumor tissues that were formalin-fixed and embedded into paraffin blocks (FFPE). Tissue samples were obtained from 39 breast cancers (BC) and 19 lung cancer (LC). The team performed the first correlation study of RNA sequencing and immunohistochemistry-measured expression profiles for the clinically actionable biomarker genes in FFPE cancer tissue samples.

RNA was extracted from FFPE sections using a QIAGEN RNeasy FFPE Kit (Hilden, Germany). The RNA 6000 Nano (Agilent Technologies, San Clara, CA, USA) or Qubit RNA Assay kits (Thermo Fisher Scientific, Waltham, MA, USA) were used to measure RNA concentration. RNA Integrity Number (RIN) was measured using Agilent 2100 Bioanalyzer. Immunohistochemistry assay for BC samples for HER2, ESR1, and PGR proteins was performed using antibody kits (Roche Diagnostics, Indianapolis, IN, USA) to identify the respective statuses of the tumors. For HER2, the output statuses were confirmed using the Roche Diagnostic’s ISH DNA Probe Cocktail assay.

The team reported that they had demonstrated high and statistically significant correlations between the RNA sequencing (Oncobox protocol, OmicsWay Corp, Walnut, CA, USA) and immunohistochemical measurements for HER2/ERBB2, ER/ESR1 and PGR genes in BC, and for PDL1 gene in LC; AUC: 0.963 for HER2, 0.921 for ESR1, 0.912 for PGR, and 0.922 for PDL1.

Anton A. Buzdin, PhD, who heads the Laboratory for Translational Genomic Bioinformatics, said, “We have shown for the first time that the findings of both methods are in perfect agreement for the selected set of biomarkers. It's just that immunohistochemistry requires a much greater number of attempts, one for every biomarker considered, meaning that much more biomaterial is needed. In turn, RNA sequencing enables us to quantitatively characterize the work of all protein-encoding genes, and there are about 20,000 of them.” The study was originally published on May 9, 2020 in the journal Biomedicines.

Print article



view channel
Image: An enzyme-linked immunosorbent assay for mannose-binding lectin found that this molecule is associated with coagulopathy in severe COVID-19 patients (Photo courtesy of Getty Images).

Mannose-Binding Lectin Associated with Coagulopathy in Severe COVID-19

The ongoing COVID-19 pandemic has caused significant morbidity and mortality worldwide, as well as profound effects on society. COVID-19 patients have an increased risk of thromboembolic (TE) complications,... Read more

Industry News

view channel

2020 AACC Annual Scientific Meeting & Clinical Lab Expo to Be an All Virtual Event Due to Coronavirus Pandemic

The American Association for Clinical Chemistry (AACC Washington, DC, USA) has decided to hold the 2020 AACC Annual Scientific Meeting & Clinical Lab Expo as a virtual event, rather than as a live... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.